Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity.

Lancel S, Hesselink MK, Woldt E, Rouillé Y, Dorchies E, Delhaye S, Duhem C, Thorel Q, Mayeuf-Louchart A, Pourcet B, Montel V, Schaart G, Beton N, Picquet F, Briand O, Salles JP, Duez H, Schrauwen P, Bastide B, Bailleul B, Staels B, Sebti Y.

JCI Insight. 2018 May 3;3(9). pii: 98081. doi: 10.1172/jci.insight.98081. [Epub ahead of print]

2.

Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice.

Pourcet B, Zecchin M, Ferri L, Beauchamp J, Sitaula S, Billon C, Delhaye S, Vanhoutte J, Mayeuf-Louchart A, Thorel Q, Haas JT, Eeckhoute J, Dombrowicz D, Duhem C, Boulinguiez A, Lancel S, Sebti Y, Burris TP, Staels B, Duez HM.

Gastroenterology. 2018 Apr;154(5):1449-1464.e20. doi: 10.1053/j.gastro.2017.12.019. Epub 2017 Dec 24.

3.

Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass.

Mayeuf-Louchart A, Thorel Q, Delhaye S, Beauchamp J, Duhem C, Danckaert A, Lancel S, Pourcet B, Woldt E, Boulinguiez A, Ferri L, Zecchin M, Staels B, Sebti Y, Duez H.

Sci Rep. 2017 Oct 30;7(1):14383. doi: 10.1038/s41598-017-14596-2.

4.

Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells.

Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J, Briand O, Dehondt H, Vallez E, Dorchies E, Baud G, Spinelli V, Hennuyer N, Caron S, Bantubungi K, Caiazzo R, Reimann F, Marchetti P, Lefebvre P, Bäckhed F, Gribble FM, Schoonjans K, Pattou F, Tailleux A, Staels B, Lestavel S.

Nat Commun. 2015 Jul 2;6:7629. doi: 10.1038/ncomms8629.

5.

Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients.

Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, Potelle C, El Arid JM, Mouton S, Sebti Y, Duez H, Preau S, Remy-Jouet I, Zerimech F, Koussa M, Richard V, Neviere R, Edme JL, Lefebvre P, Staels B.

Circulation. 2014 Aug 12;130(7):554-64. doi: 10.1161/CIRCULATIONAHA.113.008476. Epub 2014 Jun 13.

PMID:
24928681
6.

[Circadian rhythmicity and metabolism: integration of metabolic and environmental signals].

Duez H, Sebti Y, Staels B.

Med Sci (Paris). 2013 Aug-Sep;29(8-9):772-7. doi: 10.1051/medsci/2013298017. Epub 2013 Sep 5. Review. French.

7.

Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy.

Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, Hesselink MK, Paquet C, Delhaye S, Shin Y, Kamenecka TM, Schaart G, Lefebvre P, Nevière R, Burris TP, Schrauwen P, Staels B, Duez H.

Nat Med. 2013 Aug;19(8):1039-46. doi: 10.1038/nm.3213. Epub 2013 Jul 14.

8.

Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways.

Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, Staels B.

Circ Res. 2011 Apr 15;108(8):985-95. doi: 10.1161/CIRCRESAHA.110.233775. Epub 2011 Feb 24.

9.

Scrapie pathogenesis: the role of complement C1q in scrapie agent uptake by conventional dendritic cells.

Flores-Langarica A, Sebti Y, Mitchell DA, Sim RB, MacPherson GG.

J Immunol. 2009 Feb 1;182(3):1305-13.

10.

Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia.

Moreau AS, Sebti Y, Duhamel A, Roccaro AM, Coiteux V, Gastinne T, Le Friec G, Burwick N, Amiot L, Ho AW, Poulain S, Hennache B, Hunter ZR, Dessaint JP, Ghobrial IM, Treon SP, Facon T, Zorn E, Leleu X.

Eur J Haematol. 2008 Jun;80(6):503-9. doi: 10.1111/j.1600-0609.2008.01060.x. Epub 2008 Mar 10.

PMID:
18331603
11.

Soluble HLA-G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells.

Gros F, Cabillic F, Toutirais O, Maux AL, Sebti Y, Amiot L.

Eur J Immunol. 2008 Mar;38(3):742-9. doi: 10.1002/eji.200736918.

12.

Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders.

Sebti Y, Le Maux A, Gros F, De Guibert S, Pangault C, Rouas-Freiss N, Bernard M, Amiot L.

Br J Haematol. 2007 Jul;138(2):202-12.

PMID:
17593027
13.

Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages.

Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L.

Neoplasia. 2006 Mar;8(3):223-30.

14.

Capacity of myeloid and plasmacytoid dendritic cells especially at mature stage to express and secrete HLA-G molecules.

Le Friec G, Gros F, Sebti Y, Guilloux V, Pangault C, Fauchet R, Amiot L.

J Leukoc Biol. 2004 Dec;76(6):1125-33. Epub 2004 Aug 26.

PMID:
15331623
15.

HLA-G and lymphoproliferative disorders.

Amiot L, Le Friec G, Sebti Y, Drénou B, Pangault C, Guilloux V, Leleu X, Bernard M, Facon T, Fauchet R.

Semin Cancer Biol. 2003 Oct;13(5):379-85. Review.

PMID:
14708718
16.

Soluble HLA-G molecules are increased in lymphoproliferative disorders.

Sebti Y, Le Friec G, Pangault C, Gros F, Drénou B, Guilloux V, Bernard M, Lamy T, Fauchet R, Amiot L.

Hum Immunol. 2003 Nov;64(11):1093-101.

PMID:
14602240
17.

Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes.

Le Friec G, Laupèze B, Fardel O, Sebti Y, Pangault C, Guilloux V, Beauplet A, Fauchet R, Amiot L.

Hum Immunol. 2003 Aug;64(8):752-61.

PMID:
12878353

Supplemental Content

Loading ...
Support Center